Proof of principle for epitope-focused vaccine design

Nature

Volumn 507, Issue 7491, 2014, Pages 201-206

  Correia, Bruno E ^a,b,c   Bates, John T ^d   Loomis, Rebecca J ^e   Baneyx, Gretchen ^a   Carrico, Chris ^f   Jardine, Joseph G ^a,c   Rupert, Peter ^f   Correnti, Colin ^f   Kalyuzhniy, Oleksandr ^a,c   Vittal, Vinayak ^a   Connell, Mary J ^e   Stevens, Eric ^a   Schroeter, Alexandria ^a   Chen, Man ^g   MacPherson, Skye ^a,c   Serra, Andreia M ^a,c   Adachi, Yumiko ^a,c   Holmes, Margaret A ^f   Li, Yuxing ^c   Klevit, Rachel E ^a   Graham, Barney S ^g   Wyatt, Richard T ^c   Baker, David ^a   Strong, Roland K ^f   Crowe, James E ^d   Johnson, Philip R ^e   Schief, William R ^a,c   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIBODY; IMMUNOASSAY; INFECTIOUS DISEASE; INFLUENZA; MIMICRY; NEUTRALIZATION; VACCINE; VIRUS;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG DESIGN; HUMAN; IMMUNIZATION; IMMUNOLOGICAL PROCEDURES; MALE; MEDICAL RESEARCH; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHESUS MONKEY; VIRUS MORPHOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; RESPIRATORY SYNCYTIAL VIRUS;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; PROTEIN STABILITY; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84896315237     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12966     Document Type: Article

References (39)

1. Plotkin, S. A., Orenstein, W. A. & Offit, P. A. Vaccines 6th edn (Elsevier, 2012).
2. Rappuoli, R., Mandl, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nature Rev. Immunol. 11, 865-872 (2011).
3. Lozano, R. et al. Global and regionalmortality from235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
4. Murray, C. J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223 (2012).
5. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
6. The RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295 (2012).
7. Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028 (2013).
8. Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia, E. A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 36-44 (2012).
9. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
10. Anderson, L. J. et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31 (Suppl. 2), B209-B215 (2013).
11. U.S. Food and Drug Administration. Vaccines, Blood & Biologics http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
12. Burton, D. R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 706-713 (2002).
13. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183-186 (2012).
14. Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665 (2007).
15. McLellan, J. S. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nature Struct. Mol. Biol. 17, 248-250 (2010).
16. Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116-1126 (2010).
17. Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA 107, 17880-17887 (2010).
18. McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope fromrespiratory syncytial virus. J. Mol. Biol. 409, 853-866 (2011).
19. Azoitei, M. L. et al. Computation-guided backbone grafting of a discontinuousmotif onto a protein scaffold. Science 334, 373-376 (2011).
20. Azoitei, M. L. et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J. Mol. Biol. 415, 175-192 (2012).
21. Kuhlman, B. et al. Design of a novel globular protein fold with atomic-level accuracy. Science 302, 1364-1368 (2003).
22. Koga, N. et al. Principles for designing ideal protein structures. Nature 491, 222-227 (2012).
23. Correia, B. E. et al. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J. Mol. Biol. 405, 284-297 (2011).
24. Zhu, Q. et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203, 674-682 (2011).
25. Clarke, B. E. et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330, 381-384 (1987).
26. Jegerlehner, A. et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104-3112 (2002).
27. Jafri, H. S.,Wu, X., Makari, D.&Henrickson, K. J. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr. Infect. Dis. J. 32, 335-340 (2013).
28. Sundling, C. et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci. Transl. Med. 4, 142ra196 (2012).
29. Wen, X. et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nature Struct. Mol. Biol. 19, 461-463 (2012).
30. Leaver-Fay, A. et al.ROSETTA3: anobject-orientedsoftware suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545-574 (2011).
31. Rohl, C.A.,Strauss, C. E., Misura, K. M.&Baker, D. Protein structure predictionusing Rosetta. Methods Enzymol. 383, 66-93 (2004).
32. Sheffler, W. & Baker, D. RosettaHoles2: a volumetric packing measure for protein structure refinement and validation. Protein Sci. 19, 1991-1995 (2010).
33. Bansal, M., Kumar, S. & Velavan, R. HELANAL: a program to characterize helix geometry in proteins. J. Biomol. Struct. Dyn. 17, 811-819 (2000).
34. Greenfield, N. J. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nature Protocols 1, 2527-2535 (2007).
35. Greenfield, N. J. Determination of the folding of proteins as a function of denaturants, osmolytes or ligands using circular dichroism. Nature Protocols 1, 2733-2741 (2007).
36. Delaglio, F. et al. NMRPipe: a multidimensional spectral processing systembased on UNIX pipes. J. Biomol. NMR 6, 277-293 (1995).
37. Johnson, B. A.& Blevins, R. A.NMR View: a computer programfor the visualization and analysis of NMR data. J. Biomol. NMR 4, 603-614 (1994).
38. Murphy, B. R., Sotnikov, A. V., Lawrence, L. A., Banks, S. M. & Prince, G. A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalininactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502 (1990).
39. Chen, M. et al. A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J. Immunol. Methods 362, 180-184 (2010).